VBI Vaccines Inc. [NASDAQ: VBIV] traded at a high on 10/07/20, posting a 7.07 gain after which it closed the day’ session at $3.03. The company report on September 24, 2020 that VBI Vaccines to Present at Upcoming Scientific Conferences.
– World Vaccine Congress: COVID-19 panel discussion, two oral presentations highlighting Phase 3 Sci-B-Vac® data and VBI-1901 Phase 1/2a data- ID Week™: Two e-poster presentations featuring Phase 3 Sci-B-Vac® data.
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced upcoming presentations highlighting data from multiple clinical programs – including Sci-B-Vac®, the company’s 3-antigen hepatitis B vaccine; VBI-2900, the company’s coronavirus vaccine program; and VBI-1901, the company’s cancer vaccine immunotherapeutic – at the World Vaccine Congress Washington 2020 and ID Week 2020™.
The results of the trading session contributed to over 6035653 shares changing hands. Over the past one week, the price volatility of VBI Vaccines Inc. stands at 8.29% while the volatility over the past one month is 8.79%.
The market cap for VBIV stock reached $700.53 million, with 231.20 million shares outstanding and 150.88 million shares in the current float. Compared to the average trading volume of 14.62M shares, VBIV reached a trading volume of 6035653 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about VBI Vaccines Inc. [VBIV]?
Raymond James have made an estimate for VBI Vaccines Inc. shares, keeping their opinion on the stock as Strong Buy, with their previous recommendation back on August 27, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on January 16, 2019, representing the official price target for VBI Vaccines Inc. stock. Previously, the target price had yet another raise to $10, while Canaccord Genuity analysts kept a Buy rating on VBIV stock.
The Average True Range (ATR) for VBI Vaccines Inc. is set at 0.29, with the Price to Sales ratio for VBIV stock in the period of the last 12 months amounting to 384.91. The Price to Book ratio for the last quarter was 5.52.
How has VBIV stock performed recently?
VBI Vaccines Inc. [VBIV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.94. With this latest performance, VBIV shares dropped by -5.90% in over the last four-week period, additionally plugging by 220.13% over the last 6 months – not to mention a rise of 461.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VBIV stock in for the last two-week period is set at 44.73, with the RSI for the last a single of trading hit 48.14, and the three-weeks RSI is set at 45.68 for VBI Vaccines Inc. [VBIV]. The present Moving Average for the last 50 days of trading for this stock 3.56, while it was recorded at 2.85 for the last single week of trading, and 2.33 for the last 200 days.
VBI Vaccines Inc. [VBIV]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and VBI Vaccines Inc. [VBIV] shares currently have an operating margin of -2075.96 and a Gross Margin at -310.09. VBI Vaccines Inc.’s Net Margin is presently recorded at -2467.94.
Return on Total Capital for VBIV is now -42.55, given the latest momentum, and Return on Invested Capital for the company is -54.78. Return on Equity for this stock declined to -58.82, with Return on Assets sitting at -42.20. When it comes to the capital structure of this company, VBI Vaccines Inc. [VBIV] has a Total Debt to Total Equity ratio set at 18.47. Additionally, VBIV Total Debt to Total Capital is recorded at 15.59, with Total Debt to Total Assets ending up at 13.34. Long-Term Debt to Equity for the company is recorded at 0.93, with the Long-Term Debt to Total Capital now at 0.78.
Reflecting on the efficiency of the workforce at the company, VBI Vaccines Inc. [VBIV] managed to generate an average of -$438,504 per employee. Receivables Turnover for the company is 17.28 with a Total Asset Turnover recorded at a value of 0.02.
Earnings analysis for VBI Vaccines Inc. [VBIV]
With the latest financial reports released by the company, VBI Vaccines Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VBIV.
Insider trade positions for VBI Vaccines Inc. [VBIV]
There are presently around $299 million, or 44.45% of VBIV stock, in the hands of institutional investors. The top three institutional holders of VBIV stocks are: PERCEPTIVE ADVISORS LLC with ownership of 55,042,465, which is approximately 19.784% of the company’s market cap and around 5.26% of the total institutional ownership; BLACKROCK INC., holding 13,076,588 shares of the stock with an approximate value of $39.62 million in VBIV stocks shares; and VANGUARD GROUP INC, currently with $18.36 million in VBIV stock with ownership of nearly 89.965% of the company’s market capitalization.
Positions in VBI Vaccines Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 78 institutional holders increased their position in VBI Vaccines Inc. [NASDAQ:VBIV] by around 23,396,297 shares. Additionally, 24 investors decreased positions by around 2,996,112 shares, while 9 investors held positions by with 72,141,345 shares. The mentioned changes placed institutional holdings at 98,533,754 shares, according to the latest SEC report filing. VBIV stock had 40 new institutional investments in for a total of 6,098,311 shares, while 8 institutional investors sold positions of 464,447 shares during the same period.